FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Foghorn Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.87+0.02 (+1.08%)
Close on Oct 19, 2026
- Market cap
- $132.08M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-279.5%+15657.9 pts over 5 years
Net margin
-240.3%+15759.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +36.8% | +17.1% | +135.1% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -236.5% | 96.5% | |
| Return on assets | – | -49.5% | -30.8% | |
| Current ratio | – | 10.12 | 2.73 | |
| Debt to equity | – | 0.13 | – | |
| Net debt to EBITDA | – | 1.11× | – | |
| Interest coverage | – | -70.0× | – | |
| Capex to revenue | – | 3763.5% | 0.2% | |
| Diluted shares | – | 11M | 63M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Foghorn Therapeutics generated $548.47M from operations and spent $6.70M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$548.47M
Used
$6.70M
Capital expenditure$6.70M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-240.3%
×Asset turnover0.13×
×Equity multiplier-3.13×
=Return on equity, FY202596.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -240.3% | 0.13× | -3.13× | 96.5% |
| FY2024 | -383.2% | 0.08× | -4.64× | 141.2% |
| FY2023 | -288.2% | 0.10× | -8.96× | 255.4% |
| FY2022 | -566.3% | 0.04× | 9.53× | -224.5% |
| FY2021 | -7681.6% | 0.00× | 3.19× | -83.4% |
| FY2020 | -16000.0% | 0.00× | 4.78× | -236.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$74.28M
- Cash generatingOperating cash flow above zero-$86.10M
- Return on assets improvedROA up on the prior year-30.3% → -26.2%
- Earnings backed by cashOperating cash flow above net income-$86.10M vs -$74.28M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.73 → 2.73
- No dilutionShare count did not rise55M → 63M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.08 → 0.11